Skip navigation
Gamlen Instruments logo

the name change reflects our growing reputation as a provider of controlled compaction analysis instrumentation across a wide variety of markets.”

We are excited to announce that we are changing our trading name from “Gamlen Tableting” to “Gamlen Instruments”. The change acknowledges our established global presence as a leader in bench-top powder compaction instrumentation.

In addition to serving our core pharmaceutical market, Gamlen Instruments has expanded into alternative markets in food, nutrition, and a range of industrial applications which require sophisticated compact formulations involving of a wide variety of materials.

Michael Gamlen, Managing Director, comments: “From our sophisticated knowledge base in tableting science, Gamlen® powder compaction analyzers have moved beyond the boundaries of the pharmaceutical industry; the name change reflects our growing reputation as a provider of controlled compaction analysis instrumentation across a wide variety of markets.”

The company will continue to operate in its current structure, with all contact details remaining the same.
Gamlen Instruments looks forward to continued growth and product development to best serve the global pharmaceutical and materials science markets across all industries and applications.

Ends


Additional information


• Gamlen Tableting, (now trading as Gamlen Instruments) www.gamlentableting.com was established in 2011 by Dr Michael Gamlen who has over 30 years of experience on tablet development. Michael was Head of Tablet Development at The Wellcome Foundation for 15 years. He specialises in managing product development, formulation, and tablet and process development studies.

• Gamlen Tablet Presses and Powder Compaction Analyzers have been purchased by organisations all over the world including Actavis UK Ltd, De Montfort University, UK, GlaxoSmithKline (GSK) UK and US, Jordanian Pharmaceutical Company, Massachusetts Institute of Technology (MIT) US, Imperial College, UK, Sawai Pharmaceuticals, Japan, Monash University, Australia and Reckitt Benckiser UK Ltd.


For Gamlen Instruments corporate and sales enquiries, please contact:

Dr Michael Gamlen
Managing Director
Gamlen Instruments

Registered office:
BioCity Nottingham
Pennyfoot Street
Nottingham
NG1 1GF
United Kingdom


London office and demonstration laboratory:
Yeoman House
63 Croydon Road
London
SE20 7TS
United Kingdom
Tel: +44 115 912 4271

For press enquiries, please contact:

Philippa Bevan
Accelerate Associates
Tel: +44 1785 747 102 (direct)
Email: philippa@accelerate-associates.co.uk

This press release was distributed by ResponseSource Press Release Wire on behalf of Gamlen Tableting in the following categories: Medical & Pharmaceutical, for more information visit http://pressreleasewire.responsesource.com/about.